6 After-Hours Healthcare Gainers: Universe Pharma, BioAffinity, Modular Medical, Telix Pharma & More
Universe Pharmaceuticals (UPC) rose 34.89% after-hours due to multiple Schedule 13G filings. BioAffinity (BIAF) explores new uses for its CyPath Lung test, up 3%. Modular Medical (MODD) gained 7% after announcing a product launch. MAIA (MAIA) rose 6% following an insider purchase. Telix (TLX) completed a Phase 3 study, up 2.21%. aTyr Pharma (ATYR) awaits FDA response, up 4%.
How this was made
The 30-second read
Why it matters
These disclosures provide new information that can drive short‑term price action, especially in low‑float securities where ownership changes and trial milestones are material.
Market read
The article provides primary disclosures for six listed healthcare micro‑caps, each with potential short‑term trading relevance.
What to watch
Liquidity constraints and pending regulatory outcomes could cap upside despite recent gains.
Background
After‑hours trading on Tuesday featured several micro‑cap healthcare stocks moving sharply on fresh SEC filings, trial updates, and product announcements.
Ticker impact
Universe Pharmaceuticals surged 34.9% after-hours following multiple Schedule 13G filings disclosing >10% ownership stakes.
Potential short-term upside as investors reassess ownership structure.
Large insider stakes often lead to price spikes in low‑float micro‑caps.
bioAffinity announced exploration of its CyPath Lung test for post‑treatment surveillance, driving a 3% after‑hours gain.
Modest upside if trial data supports broader use.
Exploratory use without regulatory data limits immediate impact.
Modular Medical jumped >7% after‑hours after announcing launch of its Pivot tubeless patch pump in five U.S. cities.
Short‑term rally possible; long‑term depends on sales execution.
Early‑stage device launches often cause brief price spikes.
MAIA disclosed a director's purchase of 133,790 shares at $1.35‑$1.39, prompting a 6% after‑hours rise.
Likely short‑term support for the stock.
Form 4 purchases by executives can move micro‑caps.
Telix completed enrollment of 350 patients in its Phase 3 BiPASS study and has FDA review pending for a glioma agent, lifting the stock 2.2% after‑hours.
Modest upside as the study progresses toward readout.
Enrollment news is positive but impact is limited until data release.
aTyr Pharma expects FDA response on its Phase 3 sarcoidosis trial protocol, with a 4% after‑hours gain.
Limited price movement until FDA decision.
Awaited response is informational; no immediate catalyst.
Market effects
Highlights renewed investor interest in micro‑cap healthcare biotech and device firms.
U.S. small‑cap healthcare sector may see short‑term volatility.
Limited to U.S. listed micro‑caps; no broader macro effect.
Counterpoint
The spikes may be short‑lived as ownership disclosures often attract speculative buying that can reverse quickly.
Key entities
- companyUniverse Pharmaceuticals
Micro‑cap biotech reporting Schedule 13G filings.
- companybioAffinity Technologies
Developer of CyPath Lung test.
- companyModular Medical
Insulin‑delivery device maker.
- companyMAIA Biotechnology
Immunotherapy developer.
- companyTelix Pharmaceuticals
Imaging agent developer.
